Scottish swimmer Archie Goodburn met with Prime Minister Andy Burnham and Health Secretary Yvette Cooper at 10 Downing Street on Wednesday following his emotional public appeal over brain cancer care, prompting government commitments to appoint a national clinical lead, launch an expert review, and accelerate patient access to new treatments.
Archie Goodburn Meets Prime Minister Andy Burnham at Downing Street
Scottish swimmer Archie Goodburn met Prime Minister Andy Burnham on Wednesday after making an emotional appeal for more action on brain tumours. The 25-year-old athlete was joined by Health Secretary Yvette Cooper during the Downing Street visit, which followed months of public advocacy calling for systemic improvements in how the UK handles brain cancer care and research.
Goodburn was diagnosed with an oligodendroglioma at age 22 while training for Olympic try-outs. He later learned there were three inoperable brain tumours.
“Being told you have incurable cancer and have 10 to 12 years to live is devastating. Being told you have incurable cancer and have 10 to 12 years to live and there’s nothing you can do about it is even more of a blow.”
Archie Goodburn, via Brain Tumour Research
Placed on a watch-and-wait pathway to avoid the severe side effects of standard chemotherapy and radiotherapy, Goodburn eventually tracked down a treatment called vorasidenib through his studies. Goodburn began taking it in December 2025.
Government Announces Four-Step Response and Expert Review
Following the Downing Street meeting, the government announced a four-step package designed to deliver a faster route from research to treatment for people living with brain cancer. The measures include an immediate expert review led by Professor Anthony Chalmers, who serves as chairman of clinical oncology at the University of Glasgow.
Andy Burnham has announced plans for a national brain cancer clinical lead – a key plea from swimmer Archie Goodburn when he made an emotional appeal on #BBCBreakfast earlier this year. Archie met the PM in Downing Street and welcomed a package of measures including a review of… pic.twitter.com/D73xcNjqpq
The expert review will report within three months, assessing what has changed for patients since a previous 2018 government review and identifying what remains a barrier to progress. Its findings will directly shape a national action plan aimed at getting new treatments out of the laboratory and to patients faster.
In addition to the review and action plan, the government will appoint a dedicated national brain cancer clinical lead—fulfilling a core demand Goodburn made during his earlier media appearances. Prime Minister Andy Burnham also asked the Medicines and Healthcare Products Regulatory Agency (MHRA) to shorten its review timeline for rules governing rare condition medicines from three years down to two.
“Archie is an inspiration to us all, and I am determined to deliver the change patients and their families deserve. He has spoken passionately about the need for change on brain cancer, and he’s right: progress hasn’t been good enough, here or anywhere else.”
Andy Burnham, Prime Minister
Funding Disparities and Expert Demands for a Step Change
Before the Downing Street talks, Brain Tumour Research organized an open letter signed by top scientists and clinicians, warning that government targets to improve cancer survival rates will never be met for brain tumours without substantial additional investment. The letter pointed out that between 2002 and 2021, just 1% of national cancer research funding was allocated to study brain tumours.
Charity analysis indicates that three-quarters (74%) of research funding into brain tumours originates from the charity sector, while government contributions account for 26%. Figures cited by Brain Tumour Research show that in 2023–24, approximately £26.2 million was invested to study brain cancer, with £6.8 million provided by the government.
Brain tumours remain the biggest cancer killer of children and adults under the age of 40 in the UK, where around 12,500 people receive a diagnosis each year.
“The UK brain tumour community is blessed with outstanding researchers, clinicians and patient representatives but for too long has had insufficient resources and faced too many barriers. Today’s announcement offers genuine hope that we will be able to overcome these barriers and make the breakthroughs that our patients and their carers desperately need.”
Professor Anthony Chalmers, chairman of clinical oncology at the University of Glasgow
Charity Reactions and What Comes Next
Leading organizations in the cancer community welcomed the political momentum and the newly announced measures. Dr. Michele Afif, chief executive of the Brain Tumour Charity, described the package as representing a generational shift in how brain tumours are perceived and addressed nationwide.
Michelle Mitchell, chief executive of Cancer Research UK, noted that the meeting with the Prime Minister is a critical moment for people affected by this type of cancer.